Dr. Reddy's Laboratories
NYSE: RDY
$54.50
+$0.04 (+0.1%)
Closing price May 26, 2023
24/7 Wall St. is looking at some big analyst calls that we have seen so far on Tuesday, including Allstate, Electronic Arts and Zillow.
2 years ago
Is it time to buy Amarin? The biopharmaceutical company just announced a new study showing its drug Vascepa can significantly reduce cardiovascular risk in people with diabetes.
2 years ago
Amarin is on hold as generic rivals seek to copy its potential blockbuster Vascepa.
2 years ago
Last Updated: 2 years ago
Amarin is going ahead with a big marketing campaign for potential COVID treatment Vascepa after a disruption caused by the pandemic.
2 years ago
Amarin’s Vascepa treats cardiovascular disease, which is a big risk factor for COVID-19 patients, but is the subject of patent litigation.
3 years ago
Last Updated: 3 years ago
Amarin will trial Vascepa as a COVID-19 treatment and that could more than offset investor concerns about patent litigation.
3 years ago
Amarin won FDA approval for its Vascepa cardiovascular disease drug in December but the pandemic and patent litigation are weighing on the stock.
3 years ago
There are still a lot of questions for Amarin must figure out before it gets back on track. For investors, the question is whether it is the market recovery that is lifting the stock instead of the...
3 years ago
Amarin Corp. PLC (NASDAQ: AMRN) plans to mount a vigorous and speedy appeal of a U.S. District Court ruling that blocked its patents on the medication Vascepa, the company’s chief executive says....
3 years ago
Last Updated: 3 years ago
Amarin has two big problems. Getting an unfavorable court decision overruled is by far the more important.
3 years ago
Amarin stock was absolutely crushed at the tail end of March, and now the company is dealing with the fallout. Investors will be asking a lot of tough questions. Namely, is Amarin viable going...
3 years ago
Monday's top analyst upgrades, downgrades and initiations included Alibaba, AT&T, Bank of America, BlackBerry, Boeing, Citigroup, Cloudflare, DocuSign, Lululemon Athletica, Marvell Technology,...
3 years ago
Last Updated: 3 years ago
India has been one of the best growth economies measured by gross domestic product for some time, but the secular growth opportunity has faced multiple setbacks in 2018 that may persist,
4 years ago
Last Updated: 3 years ago
Everyone knows that investors will pay up to chase growth, and it is quite possible that India might be one of the best growth stories in the world for 2018 and beyond.
5 years ago
Last Updated: 3 years ago
The include Abercrombie & Fitch, Arch Coal, Baker Hughes, BioMarin Pharmaceutical, Gilead Sciences, Hasbro and Snap.
5 years ago
Last Updated: 3 years ago